98%
921
2 minutes
20
Ovarian cancer is one of the most common gynecologic cancers with the highest mortality rate over a long period. Genetic predisposition to ovarian cancer is unusually high. In the Czech Republic, causal mutation in any ovarian cancer predisposition gene is identified in approximately 30% of the ovarian cancer patients. Therefore, according to the current guidelines, all ovarian cancer patients should be provided with genetic testing. The BRCA1 and BRCA2 are the two major ovarian cancer predisposition genes. Nevertheless, mutations in other predisposition genes, including RAD51C and RAD51D, are associated with high ovarian cancer risk. Mutations in RAD51C and RAD51D are found in 1% of ovarian cancer patients in each respective gene. Currently, identification of germline mutation in RAD51C and RAD51D is primarily of preventive importance but it potentially could make a prognostic difference. The aim of this review is to summarize the recent RAD51C and RAD51D knowledge, including the biological function, cancer risks associated with germline mutations, and recommendations for mutation carriers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.48095/ccko202126 | DOI Listing |
JMIR Cancer
September 2025
iCARE Secure Data Environment & Digital Collaboration Space, NIHR Imperial Biomedical Research Centre, London, United Kingdom.
Background: Electronic health records (EHRs) are a cornerstone of modern health care delivery, but their current configuration often fragments information across systems, impeding timely and effective clinical decision-making. In gynecological oncology, where care involves complex, multidisciplinary coordination, these limitations can significantly impact the quality and efficiency of patient management. Few studies have examined how EHR systems support clinical decision-making from the perspective of end users.
View Article and Find Full Text PDFJCO Precis Oncol
September 2025
Division of Hematology and Oncology, University of California Los Angeles, Los Angeles, CA.
Purpose: mutations are classically seen in non-small cell lung cancers (NSCLCs), and EGFR-directed inhibitors have changed the therapeutic landscape in patients with -mutated NSCLC. The real-world prevalence of -mutated ovarian cancers has not been previously described. We aim to determine the prevalence of pathogenic or likely pathogenic mutations in ovarian cancer and describe a case of -mutated metastatic ovarian cancer with a durable response to osimertinib, an EGFR-directed targeted therapy.
View Article and Find Full Text PDFCien Saude Colet
August 2025
Departamento de Ciências Farmacêuticas, Universidade Federal de São Paulo. São Paulo SP Brasil.
The scope of this study was to conduct an analysis on the effect of the Age-Period-Cohort (APC) on ovarian cancer mortality in the South and Northeast regions of Brazil. The APC models were estimated by Poisson regression through estimable functions in women aged 30 and over residing in the states of the South and Northeast regions. Upon estimating the APC models, a positive gradient was found in mortality rates with advancing age in all locations The South region showed a reduction in the risk of death in the last two periods (RR2010-2014 0.
View Article and Find Full Text PDFMelanoma Res
September 2025
Gynecological Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS-CRO, National Cancer Institute Aviano, Aviano.
Peritoneal carcinomatosis represents an exceptionally rare metastatic pattern of cutaneous malignant melanoma, occurring in fewer than 1% of cases with distant spread and typically within the first few years after primary treatment. This report presents an unusual case with a markedly prolonged disease-free interval, clinically mimicking advanced ovarian carcinoma. We report the case of a 53-year-old woman treated more than 10 years ago for stage IIB nodular melanoma with surgery and adjuvant therapy.
View Article and Find Full Text PDFInt J Surg
September 2025
Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, People's Republic of China.